Literature DB >> 7675366

Relationship between race and interval to treatment in endometrial cancer.

J R Liu1, M Conaway, G C Rodriguez, J T Soper, D L Clarke-Pearson, A Berchuck.   

Abstract

OBJECTIVE: To determine whether the poor prognosis of black women with endometrial adenocarcinoma is due to racial differences in the interval between the onset of abnormal uterine bleeding and hysterectomy.
METHODS: Clinical records of all 219 patients (176 white, 39 black, four other) who underwent surgical treatment of endometrial cancer during 1990-1993 at our institution were reviewed to obtain information regarding clinicopathologic features. In addition, the interval between the onset of abnormal uterine bleeding and hysterectomy was noted.
RESULTS: Compared with white patients, black women with endometrial cancer had a significantly higher incidence of unfavorable features, including non-endometrioid histology (38 versus 12%), stage III or IV disease (51 versus 19%), grade 3 differentiation (49 versus 18%), and poor survival (P = .003). There was no significant difference in the median interval from onset of abnormal uterine bleeding to hysterectomy between blacks (11.1 weeks) and whites (13.7 weeks), nor was the interval to treatment related to stage, grade, histologic type, myometrial invasion, or survival. In contrast, patients with a history of hormone use had a longer median interval from the onset of abnormal bleeding to treatment compared with patients who had not used hormones (19 versus 10 weeks) (P < .01), and hormone use was associated with favorable clinicopathologic features and survival. Although black women were less likely to have used hormones than white women (13 versus 44%) (P < .001), racial differences in stage, grade, and survival persisted after correcting for hormone use.
CONCLUSION: This study confirms that black women with endometrial cancer have a poorer outcome than white women; however, this does not appear to be due to a difference in the interval from onset of abnormal uterine bleeding to hysterectomy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675366     DOI: 10.1016/0029-7844(95)00238-m

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

Review 1.  Racial and ethnic disparities in cancers of the uterine corpus.

Authors:  O W Stephanie Yap; Roland P Matthews
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

2.  Racial differences in surgically staged patients with endometrial cancer.

Authors:  M L Hicks; W Kim; J Abrams; C C Johnson; A C Blount; G P Parham
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

Review 3.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

4.  Impact of age at diagnosis on racial disparities in endometrial cancer patients.

Authors:  Christopher M Tarney; Chunqiao Tian; Guisong Wang; Elizabeth A Dubil; Nicholas W Bateman; John K Chan; Mohamed A Elshaikh; Michele L Cote; Joellen M Schildkraut; Craig D Shriver; Thomas P Conrads; Chad A Hamilton; G Larry Maxwell; Kathleen M Darcy
Journal:  Gynecol Oncol       Date:  2017-08-08       Impact factor: 5.482

5.  Access to hematopoietic stem cell transplantation: effect of race and sex.

Authors:  Thomas V Joshua; J Douglas Rizzo; Mei-Jie Zhang; Parameswaran N Hari; Seira Kurian; Marcelo Pasquini; Navneet S Majhail; Stephanie J Lee; Mary M Horowitz
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

6.  Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival.

Authors:  Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber
Journal:  Am J Public Health       Date:  2004-12       Impact factor: 9.308

7.  Racial disparities in risk of second primary cancers in endometrial cancer patients: Analysis of SEER Data.

Authors:  Ashley S Felix; Faina Linkov; G Larry Maxwell; Camille Ragin; Emanuela Taioli
Journal:  Int J Gynecol Cancer       Date:  2011-02-01       Impact factor: 3.437

8.  More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer.

Authors:  David A Barrington; Jennifer A Sinnott; Danaye Nixon; Tasleem J Padamsee; David E Cohn; Kemi M Doll; Macarius M Donneyong; Ashley S Felix
Journal:  Am J Obstet Gynecol       Date:  2022-03-10       Impact factor: 10.693

9.  Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?

Authors:  G Larry Maxwell; Chunqiao Tian; John I Risinger; Chad A Hamilton; Richard R Barakat
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

10.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Authors:  Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.